{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:41:21Z","timestamp":1792636881802,"version":"4.5.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:p>Managing bone health after denosumab cessation is a commonly encountered challenge. Although the \u201crebound phenomenon\u201d is generally recognized by endocrinologists in the context of osteoporosis, it is not as widely understood in the context of bone metastases and cancer. This commentary reviews the evidence on the efficacy and safety of various bone health agents in mitigating the \u201crebound phenomenon\u201d in cancer populations.<\/jats:p>","DOI":"10.1093\/oncolo\/oyac213","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T18:38:03Z","timestamp":1666031883000},"page":"998-1003","source":"Crossref","is-referenced-by-count":10,"title":["Bone Health and Denosumab Discontinuation in Oncology Populations"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3875-5698","authenticated-orcid":false,"given":"Yee-Ming Melody","family":"Cheung","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women\u2019s Hospital, and Harvard Medical School, Boston , MA , USA"},{"name":"Department of Medicine, Endocrine Unit, Austin Hospital, The University of Melbourne, Victoria , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Morgans","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston , MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole-Petter Riksfjord","family":"Hamnvik","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women\u2019s Hospital, and Harvard Medical School, Boston , MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"key":"2022120904441193600_CIT0001","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/jcm10010152","article-title":"Denosumab discontinuation and the rebound phenomenon: a narrative review","volume":"101","author":"Anastasilakis","year":"2021","journal-title":"J Clin Med"},{"key":"2022120904441193600_CIT0002","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","article-title":"Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Gnant","year":"2019","journal-title":"Lancet Oncol"},{"key":"2022120904441193600_CIT0003","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"key":"2022120904441193600_CIT0004","first-page":"CD003474","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"10","author":"O\u2019Carrigan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2022120904441193600_CIT0005","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022120904441193600_CIT0006","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00520-013-2094-y","article-title":"Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems","volume":"22","author":"Oster","year":"2014","journal-title":"Support Care Cancer"},{"key":"2022120904441193600_CIT0007","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00520-009-0645-z","article-title":"Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting","volume":"18","author":"Trinkaus","year":"2010","journal-title":"Support Care Cancer"},{"key":"2022120904441193600_CIT0008","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3816\/CBC.2007.n.027","article-title":"Patterns of bisphosphonate use in the United States in the treatment of metastatic bone disease","volume":"7","author":"Mortimer","year":"2007","journal-title":"Clin Breast Cancer"},{"key":"2022120904441193600_CIT0009","year":"2014"},{"key":"2022120904441193600_CIT0010","year":"2010"},{"key":"2022120904441193600_CIT0011","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11914-019-00502-4","article-title":"Stopping denosumab","volume":"17","author":"Lamy","year":"2019","journal-title":"Curr Osteoporos Rep"},{"key":"2022120904441193600_CIT0012","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2022120904441193600_CIT0013","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of Denosumab: a post hoc analysis of the randomized placebo-controlled freedom trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2022120904441193600_CIT0014","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial","volume":"35","author":"Solling","year":"2020","journal-title":"J Bone Miner Res"},{"key":"2022120904441193600_CIT0015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10549-019-05458-8","article-title":"Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors","volume":"179","author":"Gonzalez-Rodriguez","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"2022120904441193600_CIT0016","doi-asserted-by":"crossref","first-page":"100423","DOI":"10.1016\/j.jbo.2022.100423","article-title":"Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: a real-world machine learning approach","volume":"34","author":"Jacobson","year":"2022","journal-title":"J Bone Oncol"},{"key":"2022120904441193600_CIT0017","article-title":"Fracture risk after stopping adjuvant denosumab in hormone receptor positive breast cancer patients on aromatase inhibitor therapy- An analysis of 3,425 postmenopausal patients in the phase III ABCSG-18 trial (abstract LB-1167).","author":"Pfeiler","year":"2018"},{"key":"2022120904441193600_CIT0018","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.mayocpiqo.2019.02.003","article-title":"Rebound vertebral fractures in a patient with lung cancer after oncology-dose denosumab discontinuation: a cautionary tale","volume":"3","author":"Tyan","year":"2019","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"2022120904441193600_CIT0019","doi-asserted-by":"crossref","first-page":"101582","DOI":"10.1016\/j.bonr.2022.101582","article-title":"Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases","volume":"16","author":"Dupont","year":"2022","journal-title":"Bone Rep"},{"key":"2022120904441193600_CIT0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"key":"2022120904441193600_CIT0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"key":"2022120904441193600_CIT0022","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Clinical Practice Guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2022120904441193600_CIT0023","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2022120904441193600_CIT0024","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diab Endocrinol"},{"key":"2022120904441193600_CIT0025","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol"},{"key":"2022120904441193600_CIT0026","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1172\/JCI118722","article-title":"Bisphosphonates: mechanisms of action","volume":"97","author":"Rodan","year":"1996","journal-title":"J Clin Invest"},{"key":"2022120904441193600_CIT0027","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1172\/JCI115539","article-title":"Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure","volume":"88","author":"Sato","year":"1991","journal-title":"J Clin Invest"},{"key":"2022120904441193600_CIT0028","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2022120904441193600_CIT0029","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"2022120904441193600_CIT0030","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"2022120904441193600_CIT0031","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/jbmr.3853","article-title":"Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial","volume":"34","author":"Anastasilakis","year":"2019","journal-title":"J Bone Miner Res"},{"key":"2022120904441193600_CIT0032","doi-asserted-by":"crossref","first-page":"e4155","DOI":"10.1210\/clinem\/dgab321","article-title":"The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation","volume":"106","author":"Makras","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2022120904441193600_CIT0033","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/jbmr.4305","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study","volume":"36","author":"S\u00f8lling","year":"2021","journal-title":"J Bone Miner Res"},{"key":"2022120904441193600_CIT0034","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jocd.2006.07.005","article-title":"Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy","volume":"9","author":"Bruder","year":"2006","journal-title":"J Clin Densitom"},{"key":"2022120904441193600_CIT0035","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1210\/clinem\/dgz095","article-title":"Bone mineral density after transitioning from denosumab to alendronate","volume":"105","author":"Kendler","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2022120904441193600_CIT0036","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1200\/JCO.2007.15.2967","article-title":"Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial","volume":"26","author":"Greenspan","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022120904441193600_CIT0037","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.ijrobp.2012.11.007","article-title":"Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy","volume":"85","author":"Choo","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022120904441193600_CIT0038","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00223-018-0404-6","article-title":"Bone loss after romosozumab\/denosumab: effects of bisphosphonates","volume":"103","author":"Horne","year":"2018","journal-title":"Calcif Tissue Int"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/12\/998\/47751609\/oyac213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/12\/998\/47751609\/oyac213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T04:44:39Z","timestamp":1670561079000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/12\/998\/6762063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,17]]},"references-count":38,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,10,17]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac213","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,10,17]]}}}